Qlaris Bio Appoints New CEO as IOP Drop Enters Phase 3 Trials
Qlaris Bio Taps Fred Guerard as Novel President and CEO
Qlaris Bio, a biopharmaceutical company focused on developing novel therapies for glaucoma and ocular hypertension, announced today the appointment of Fred Guerard, PharmD, as its new President and Chief Executive Officer. This leadership change comes as the company prepares to initiate phase 3 clinical trials for its lead candidate, QLS-111, an innovative eye drop designed to lower intraocular pressure (IOP). The move signals a pivotal moment for Qlaris Bio as it advances toward potential commercialization of a new treatment option for these common eye conditions.
QLS-111 Enters Phase 3 Development
The core of Qlaris Bio’s progress lies in QLS-111, a novel eye drop currently under investigation for its ability to reduce IOP in patients diagnosed with open-angle glaucoma and ocular hypertension (OHT). Phase 2 clinical trials, named Osprey and Apteryx, have demonstrated promising results, paving the way for the upcoming phase 3 development. Details of the Phase 2 trials indicate the drug met all primary and secondary endpoints, suggesting a potential benefit for patients. Guerard highlighted the “encouraging clinical data and a differentiated mechanism targeting episcleral venous pressure” as key factors driving the company forward.
A Seasoned Leader at the Helm
Fred Guerard brings a wealth of experience to Qlaris Bio, having previously held leadership positions at several prominent ophthalmology-focused companies. He most recently served as CEO of Opthea, and before that, as president and CEO of Graybug Vision. His background likewise includes a tenure as worldwide franchise head of ophthalmology at Novartis. This extensive experience in both biotechnology and large pharmaceutical organizations positions him well to guide Qlaris Bio through its next phase of growth.
Ron Hunt, chairman of the board of Qlaris, emphasized Guerard’s proven ability to build high-performing teams and drive both clinical and commercial success. “His leadership will be invaluable as we enter this pivotal stage of growth,” Hunt stated in a press release.
Transition of Leadership
Guerard succeeds Qlaris Bio co-founder Thurein Htoo, who previously held the roles of president and CEO. Wende Hutton, a member of the board of directors and general partner at Canaan Partners, expressed gratitude for Htoo’s contributions in leading the company to this critical juncture. “Qlaris is now in a strong position to take QLS-111 through late-stage development, and we wish to thank Thurein for his outstanding efforts,” Hutton said.
Understanding Glaucoma and Ocular Hypertension
Glaucoma is a group of eye diseases that damage the optic nerve, often leading to vision loss and blindness. The Centers for Disease Control and Prevention (CDC) estimates that over 3 million Americans have glaucoma, and this number is expected to rise with an aging population. Ocular hypertension (OHT) is a condition where the pressure inside the eye (IOP) is higher than normal, but without any detectable optic nerve damage. While not everyone with OHT develops glaucoma, This proves considered a major risk factor.
IOP is a key modifiable risk factor for glaucoma. Current treatments often involve eye drops, laser procedures, or surgery to lower IOP and prevent further optic nerve damage. QLS-111’s mechanism of action, targeting episcleral venous pressure, offers a potentially novel approach to IOP reduction.
The Significance of Episcleral Venous Pressure
Episcleral venous pressure refers to the pressure within the veins located on the surface of the eye. Elevated pressure in these veins can contribute to increased IOP. QLS-111 is designed to modulate this pressure, potentially providing a more targeted and effective way to lower IOP compared to traditional treatments. The phase 2 trial results suggest this approach may be successful, but further investigation in phase 3 trials is necessary to confirm these findings.
What’s Next for Qlaris Bio and QLS-111?
The immediate focus for Qlaris Bio is the initiation and completion of phase 3 clinical trials for QLS-111. These trials will involve a larger number of patients and will be designed to confirm the efficacy and safety of the drug. Successful completion of phase 3 trials would be a significant milestone, paving the way for regulatory submissions to health authorities, such as the Food and Drug Administration (FDA) in the United States, for potential market approval. The company can be reached for further information at [email protected].
Beyond QLS-111, Qlaris Bio may explore additional applications of its technology platform and investigate other potential therapies for glaucoma and related eye conditions. The company’s long-term success will depend on its ability to continue innovating and developing effective treatments for these debilitating diseases.